| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 04/30/2009 | WO2009053026A2 Process for producing carnosol from carnosic acid using hydrogen peroxide or peracids |
| 04/30/2009 | WO2009052972A2 Use of norgestimate as a selective inhibitor of trpc3, trpc6 and trpc7 ion channels |
| 04/30/2009 | WO2009052970A2 Compounds for use in imaging, diagnosing, and/or treatment of diseases of the central nervous system or of tumors |
| 04/30/2009 | WO2009052924A1 Process for producing carnosol from carnosic acid |
| 04/30/2009 | WO2009052895A1 Aspalathin-like dihydrochalcone, extracts from unfermented rooibos and process for preparation |
| 04/30/2009 | WO2009052711A1 New compounds isolated from extract of antrodia camphorata |
| 04/30/2009 | WO2009052708A1 1-(3-amino-propyl)-piperidin-4-yl-amides, pharmaceutical compositions, processes for their preparation and uses |
| 04/30/2009 | WO2009052630A1 Compositions and methods for treating fibroproliferative disorders |
| 04/30/2009 | WO2009052629A1 Compositions and methods for enhancing immune response |
| 04/30/2009 | WO2009052625A1 Novel crystalline salts of montelukast |
| 04/30/2009 | WO2009052624A1 Inhalation compositions comprising montelukast acid and a pde-4 inhibitor or an inhaled corticosteroid |
| 04/30/2009 | WO2009052617A1 Treatment regime for proliferative disorders |
| 04/30/2009 | WO2009052591A1 Method of treatment with potentised stereoisomer of glutamate |
| 04/30/2009 | WO2009052569A1 A method and medicament for pain management |
| 04/30/2009 | WO2009052566A1 Anti-microbial composition |
| 04/30/2009 | WO2009039362A3 Chiral synthesis of diazepinoquinolines |
| 04/30/2009 | WO2009035855A3 Novel uses of halogenated alkyl sulfonamides |
| 04/30/2009 | WO2009033039A3 Buffer solutions having selective bactericidal activity against gram negative bacteria and methods of using same |
| 04/30/2009 | WO2009032885A3 Piperidinylamino-thieno[2,3-d] pyrimidine compounds for treating fibrosis |
| 04/30/2009 | WO2009032034A3 Stabilized picoplatin dosage form |
| 04/30/2009 | WO2009031011A3 Xinafoate salt of n4-(2, 2-difluoro-4h-benz0 [1,4] 0xazin-3-one) -6-yl] -5-fluoro-n2- [3- (methylaminocar bonylmethyleneoxy) phenyl] 2, 4-pyrimidinediamine |
| 04/30/2009 | WO2009030862A3 Use of travoprost for treating hair loss |
| 04/30/2009 | WO2009030725A3 Azaindoles as inhibitors of soluble adenylate cyclase |
| 04/30/2009 | WO2009029681A3 Micrornas for inhibiting viral replication |
| 04/30/2009 | WO2009028900A3 Oral administration drug comprising clopidogrel besylate |
| 04/30/2009 | WO2009027955A3 Detoxification composition and method of detoxifying the body |
| 04/30/2009 | WO2009027644A8 Compositions for the treatment of neoplastic diseases |
| 04/30/2009 | WO2009027077A8 5-arylalkylidene-2-arylalkyl-thiazol-4-one derivatives as inhibitors of 5-lipoxygenase and uses thereof |
| 04/30/2009 | WO2009027069A3 Osmolytes for the treatment of allergic or viral respiratory diseases |
| 04/30/2009 | WO2009026422A3 Treatment of central nervous system disorders |
| 04/30/2009 | WO2009026169A3 Oncotherapeutic application of inhibitors of high-affinity glucose transporters |
| 04/30/2009 | WO2009025839A3 Phosphodiesterase 10 inhibitors |
| 04/30/2009 | WO2009023126A3 Bicyclic amides for enhancing glutamatergic synaptic responses |
| 04/30/2009 | WO2009022216A9 Rna sequence motifs in the context of defined internucleotide linkages inducing specific immune modulatory profiles |
| 04/30/2009 | WO2009021169A3 (7h-pyrr0l0 [2, 3-d] pyrimidin-4-yl) -piperazines as kinase inhibitors for the treatment of cancer and inflammation |
| 04/30/2009 | WO2009019555A3 Ophthalmic formulation containing paracetamol |
| 04/30/2009 | WO2009017848A9 Compounds, compositions, and methods for the treatment of amyloid diseases such as systemic aa amyloidosis |
| 04/30/2009 | WO2009017837A3 Sublingual fentanyl spray |
| 04/30/2009 | WO2009016677A3 Continuous process for microspheres production by using expanded fluids |
| 04/30/2009 | WO2009015037A3 5-pyridinone substituted indazoles |
| 04/30/2009 | WO2009014624A3 Nrf2 inducers for treating epidermolysis bullosa simplex |
| 04/30/2009 | WO2009011910A3 Imidazolidinone compounds, methods to inhibit deubiquitination and methods of treatment |
| 04/30/2009 | WO2009011871A3 Thiadiazole modulators of pkb |
| 04/30/2009 | WO2009010429A3 Novel heterocyclyl compounds and their use as chemokine antagonists |
| 04/30/2009 | WO2009009067A3 Micelle encapsulation of theropeutic agents |
| 04/30/2009 | WO2009007441A3 Crystalline form of (e) 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2 pyrimidinyl]amino]benzonitrile |
| 04/30/2009 | WO2009004164A3 Diazeniumdiolate derivatives, method for preparing same and pharmaceutical compositions containing same |
| 04/30/2009 | WO2009003711A3 Stereoisomers of tricyclodecan-9-yl-xanthogenate |
| 04/30/2009 | WO2008151022A3 Nucleic acid nanoparticles and uses therefor |
| 04/30/2009 | WO2008146251A3 A primary micro rna expression cassette |
| 04/30/2009 | WO2008141119A3 Modulators of cftr |
| 04/30/2009 | WO2008140553A4 Mapk/erk kinase inhibitors |
| 04/30/2009 | WO2008140545A3 Inhibiting smad signaling promotes neuron regeneration |
| 04/30/2009 | WO2008140421A3 Heterocycloalkyl substituted pyrimidine derivatives |
| 04/30/2009 | WO2008140420A3 Pyrimidine derivatives |
| 04/30/2009 | WO2008140419A3 Pyridyl substituted pyrimidine derivatives |
| 04/30/2009 | WO2008138889A3 3, 6-disubstituted-imidazo [1, 2-b] pyridazines and 3, 5-disubstituted pyrazolo[1, 5-a] pyrimidines as phosphatidylinositol-3-kinase inhibitors |
| 04/30/2009 | WO2008138605A3 Method for producing n-methylnaltrexone bromide |
| 04/30/2009 | WO2008132608A3 Combined use of egf pathway inhibitors and differentiation promoting compounds |
| 04/30/2009 | WO2008127594A3 Combination therapies comprising quinoxaline inhibitors of pi3k-alpha for use in the treatment of cancer |
| 04/30/2009 | WO2008126123A3 Water-soluble coronene derivatives active as inhibitors of telomerase |
| 04/30/2009 | WO2008124129A3 Treating hiv with a m-csf effector kinase inhibitor like imatinib |
| 04/30/2009 | WO2008119042A3 Combination of blys inhibition and/or april inhibition and immunnosuppressants for treatment of autoimmune disease |
| 04/30/2009 | WO2008116226A8 Magnesium compositions and uses thereof |
| 04/30/2009 | WO2008110351A3 Use of (r) and (s)-2-aryl-propionic acid derivatives as antiseptic agents |
| 04/30/2009 | WO2008109375A4 Nucleic acid compounds for inhibiting pik3c gene expression and uses thereof |
| 04/30/2009 | WO2008102017A3 Food comprising polyunsaturated fatty acids for the prevention of chronic diseases |
| 04/30/2009 | WO2008097249A3 Method for the treatment of anthrax toxicity |
| 04/30/2009 | WO2008094969A3 Combination therapy with angiogenesis inhibitors |
| 04/30/2009 | WO2008085611A3 Designer theraphy of pancreatic tumors |
| 04/30/2009 | WO2008073779A3 Compositions and methods for treating seizures |
| 04/30/2009 | WO2008070616A3 METHODS AND COMPOSITIONS RELATED TO HIF-1α |
| 04/30/2009 | WO2008068778A8 Extended release pharmaceutical composition of pramipexole |
| 04/30/2009 | WO2008061109A3 Indazole derivatives useful as melanin concentrating receptor ligands |
| 04/30/2009 | WO2008053446A3 Benzoxazepine compounds, their preparation and use |
| 04/30/2009 | WO2008046598A8 DERIVATIVES OF 4-(2-AMINO-1-HYDROXYETHYL)PHENOL AS AGONISTS OF THE β2 ADRENERGIC RECEPTOR |
| 04/30/2009 | WO2008027357A9 Pharmaceutical compositions of clonazepam and methods of use thereof |
| 04/30/2009 | WO2008021559A3 Crystalline and amorphous forms of tiagabine |
| 04/30/2009 | WO2008017692A3 Methods, uses and compositions for modulating replication of hcv through the farnesoid x receptor (fxr) activation or inhibition |
| 04/30/2009 | WO2008017000A8 Methods and pharmaceutical preparations for contributing to the treatment of chemotherapy-induced neuropathy |
| 04/30/2009 | WO2008012621A3 Compositions and meth0ds for inhibiting gastric acide secretion using derivatives of small dicarboxylic acids in combination with ppi |
| 04/30/2009 | WO2008001380A3 Method of treatment of age-related macular degeneration |
| 04/30/2009 | WO2008001368A3 Use of stilbene derivatives for treatment and prevention of aquatic mold infections |
| 04/30/2009 | WO2007109172A3 Bicycloheteroaryl compounds as p2x7 modulators and uses thereof |
| 04/30/2009 | WO2007095497A9 Compositions and methods for prevention and treatment of cachexia |
| 04/30/2009 | WO2007094825A3 Metaxalone products, method of manufacture, and method of use |
| 04/30/2009 | WO2007078340A3 Boron-containing small molecules |
| 04/30/2009 | WO2007061942A3 Compositions for disrupting and inhibiting reconstitution of wound biofilm |
| 04/30/2009 | WO2007061717A3 Methods for isolating propargylated aminoindans |
| 04/30/2009 | WO2007059099A3 Boroproline combination therapy for cancer |
| 04/30/2009 | WO2007058850A3 Inhibitors of akt activity |
| 04/30/2009 | WO2007056213A3 Drug-eluting stents coated with p2y12 receptor antagonist compound |
| 04/30/2009 | WO2007056016A3 Bisamide cytokine inhibitors |
| 04/30/2009 | WO2007053580A3 Sigma ligands for neuronal regeneration and functional recovery |
| 04/30/2009 | WO2007050554A3 Methods for identifying compounds that modulate phb domain protein activity and compositions thereof |
| 04/30/2009 | WO2007050369A3 Topical pain relief compositions of n,2,3-trimethyl-2-isopropylbutamide and methods for using the same |
| 04/30/2009 | WO2007048004A3 Compounds for enhancing hypoxia inducible factor activity and methods of use |
| 04/30/2009 | WO2007047253A3 Pharmaceutical formulations of cyclodextrins and antifungal azole compounds |
| 04/30/2009 | WO2007044982A3 Methods for the preservation of platelet efficacy during storage |
| 04/30/2009 | WO2007044945A3 Mineral collagen chelates and methods of making and using same |